Stellate Ganglion Block on Gastroesophageal Reflux Disease
NCT06319521 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2024-03-20
Summary
The goal of this clinical trial is to explore Clinical Effect of Stellate Ganglion Block on Gastroesophageal Reflux Disease. The main question it aims to answer is:
• Can stellate ganglion block improve gastroesophageal reflux symptoms better on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Stellate Ganglion Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, Self-Evaluation Questionnaire for Gastroesophageal Reflux Disease, to see if the Stellate Ganglion Block can help improve the symptom.
Conditions
- Gastroesophageal Reflux Disease
Interventions
- BEHAVIORAL
-
Rehabilitation therapy
Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.
- PROCEDURE
-
Stellate ganglion block
The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
- DRUG
-
Lidocaine hydrochloride
Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
- PROCEDURE
-
Placebo injection
1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Sponsors & Collaborators
-
Copka Sonpashan
lead OTHER_GOV
Principal Investigators
-
Nieto Luis · Site Coordinator of United Medical Group
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-31
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
More Related Trials
-
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
NCT00734747 ·Status: COMPLETED ·Phase: PHASE3
-
Radiofrequency Energy Delivery for Gastroesophageal Reflux Disease
NCT03223116 ·Status: UNKNOWN ·Phase: NA
-
Treatment Of Gastroesophageal Reflux Disease By Endoscopic Fundoplication, A Placebo-Controlled Study
NCT00235677 ·Status: COMPLETED ·Phase: PHASE3
-
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
NCT07004439 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
NCT00963144 ·Status: COMPLETED
-
Stretta Treatment in GERD After SG
NCT05094895 ·Status: UNKNOWN ·Phase: NA
-
STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD
NCT02935881 ·Status: UNKNOWN ·Phase: PHASE3
-
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
NCT03299985 ·Status: COMPLETED ·Phase: NA
-
Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome
NCT05312463 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD
NCT07004400 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Fermented Soybean (FSB) Supplementation on Gas-troesophageal Reflux Disease (GERD)
NCT06524271 ·Status: COMPLETED ·Phase: NA
-
Effect of Manual Diaphragmatic Activation on Diaphragm Function in Patients With Gastroesophageal Reflux Disease
NCT06268548 ·Status: RECRUITING ·Phase: NA
-
Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair
NCT04795934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain
NCT03319121 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Stretta Versus Conservative Treatment
NCT05781347 ·Status: RECRUITING ·Phase: NA
-
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
NCT00703534 ·Status: COMPLETED ·Phase: PHASE2
-
Radiofrequency Ablation vs Sham Procedure for Symptomatic Cervical Inlet Patch
NCT03471052 ·Status: UNKNOWN ·Phase: NA
-
the Efficency and Safety of Stretta in GERD
NCT03574831 ·Status: UNKNOWN
-
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
NCT05870163 ·Status: RECRUITING
-
Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux
NCT00414856 ·Status: COMPLETED ·Phase: PHASE1
-
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
NCT06984484 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)
NCT01161602 ·Status: COMPLETED ·Phase: PHASE2
-
ThickenUp® Gel Express for Patients with Dysphagia
NCT04741581 ·Status: COMPLETED ·Phase: NA
-
Management of Reflux After Sleeve Using Stretta
NCT02637713 ·Status: TERMINATED ·Phase: NA
-
Design and Implementation of a Nutritional Intervention in Patients With Oropharyngeal Dysphagia
NCT02959450 ·Status: COMPLETED ·Phase: NA